20-(B)-20,25-dihydroperoxy-3β-hydroxycholest-5-ene and 20-(S)-20,25-dihydroperoxy-3β-hydroxycholest-5-ene

Abstract

A method is provided for suppressing atherogenesis in which <DEL-S DATE="20030218" ID="DEL-S-00001"/>a cholesterol 20-hydroperoxide is administered, which is preferably one or both of the novel compounds: 20(R)-hydroperoxy-25-hydrocholesterol and 29(S)-hydroperoxy-25-hydrocholesterol<DEL-E ID="DEL-S-00001"/> <INS-S DATE="20030218" ID="INS-S-00001"/>20(R)-hydroperoxy-25 hydrocholesterol and 20(S)-hydroperoxy-25-hydrocholesterol are administered. The compositions 20(R)-hydroperoxy-25-hydrocholesterol and 20(S)-hydroperoxy-25-hydrocholesterol are also provided<INS-E ID="INS-S-00001"/>.

We claim:  
     
       1. A method of suppressing atherogenesis in a human patient, comprising administering to the patient an amount of a cholesterol 20-hydroperoxide selected from the group consisting of 20(R)-hydroperoxy-25-hydroxycholesterol, 20(S)-hydroperoxy-25-hydroxycholesterol and mixtures thereof  A method of suppressing atherogenesis in a human patient, comprising administering to the patient an amount of a cholesterol hydroperoxide selected from the group consisting of  20 -( R )-   20 , 25   - dihydroperoxy -   3 β - hydroxycholest -   5   - ene,  20   -( S )-   20 , 25   - dihydroperoxy -   3 β - hydroxycholest -   5   - ene and mixtures thereof  effective for reducing aortal deposit of cholesterol, said amount administered being in a dosage range from 0.5 to 25 milligrams of said cholesterol 20-  hydroperoxide per kilogram of body weight per 24 hours. 
     
     
       2. The method of  claim 1  in which the  said cholesterol 20-  hydroperoxide is administered orally. 
     
     
       3. A medication for prevention and/or treatment of atherogenesis in human patients, comprising an oral dose form of cholesterol 20-  hydroperoxide,  selected from the group consisting of  20 -( R )-   20 , 25   - dihydroperoxy -   3 β - hydroxycholest -   5   - ene,  20   -( S )-   20 , 25   - dihydroperoxy -   3 β - hydroxycholest -   5   - ene and mixtures thereof,  said dose form being selected from tablets and capsules. 
     
     
       4. The medication of  claim 3  in which said cholesterol 20-  hydroperoxide is in admixture with a solid carrier. 
     
     
       5. The medication of  claim 3  in which said dose form is a tablet, and said cholesterol 20-  hydroperoxide is admixed with a pharmaceutical tabletting composition. 
     
     
       6. The medication of  claim 3  in which said dose form is a capsule, and said cholesterol 20-  hydroperoxide is admixed with a pharmaceutical diluent composition. 
     
     
       7. The medication of claims  3 ,  4 ,  5 , or  6  in which said cholesterol 20-hydroperoxide is selected from the group consisting of 20(R)-hydroperoxy-25-hydroxycholesterol, 20(S)-hydroperoxy-25-hydroxycholesterol, and mixtures thereof. 
     
     
       8. 20(R)-hydroperoxy-25-hydroxycholesterol   20 -( R )-   20 , 25   - dihydroperoxy -   3 β - hydroxycholest -   5   - ene . 
     
     
       9. 20(S)-hydroperoxy-25-hydroxycholesterol   20 -( S )-   20 , 25   - dihydroxyperoxy -   3 β - hydroxycholest -   5   - ene .